The influence between migraine preven drugs and sumatriptan succinate on motor activity

Authors

  • Edison Matos Novak Headache Unit Health Science Experimental Laboratory (LESC) – UFPR
  • Pedro André Kowacs Headache Unit, Neurology Division, Internal Medicine Department, Hospital de Clínicas, Federal University of Paraná (HC/UFPR), Curitiba PR, Brazil https://orcid.org/0000-0001-7770-7475
  • Guilherme Armando de Carvalho Headache Unit Health Science Experimental Laboratory (LESC) – UFPR.
  • Mariane Christina Savio Headache Unit Health Science Experimental Laboratory (LESC) – UFPR.
  • Lucas Pires Augusto Headache Unit Health Science Experimental Laboratory (LESC) – UFPR.
  • Conrado Regis Borges Headache Unit
  • Gustavo Ribas Headache Unit, Neurology Division, Internal Medicine Department, Hospital de Clínicas, Federal University of Paraná (HC/UFPR), Curitiba PR, Brazil
  • Giovana Costa Guinski Headache Unit, Neurology Division, Internal Medicine Department, Hospital de Clínicas, Federal University of Paraná (HC/UFPR), Curitiba PR, Brazil
  • Sandra Monarin Headache Unit, Neurology Division, Internal Medicine Department, Hospital de Clínicas, Federal University of Paraná (HC/UFPR), Curitiba PR, Brazil.
  • Marco Antonio Takashi Utiumi Centro de Cefaleia da Clínica de Neurologia São José https://orcid.org/0000-0001-5273-6798
  • Élcio Juliato Piovesan Headache Unit Health Science Experimental Laboratory (LESC) – UFPR

DOI:

https://doi.org/10.48208/HeadacheMed.2024.30

Keywords:

anxiogenic, anxiolitic, Motor activity, Migraine, migraine prophylaxis, sumatriptana succinato

Abstract

Background and aim

The motor effect of sumatriptan succinate (SS) and whether or not it is associated
with different classes of migraine preventive drugs has yet to be studied. We aimed to analyze such drugs' influence on animal motor activity, verifying their effect when used alone or in combination.

Methods

Male Norvegicus rats (n=98) were treated with routinely prescribed migraine preventive drugs and divided into five groups: isotonic saline solution (ISS, control), propranolol, topiramate, flunarizine, and amitriptyline. After five days of daily treatment, the animals received acute treatment with either ISS or Sumatriptan succinate (SS). The drug's influence on motor function behavior was assessed with the rotarod and open field tests.

Results

Propranolol and flunarizine interfered with the motor activity (p=0.006 and 0.002, respectively). SS did not cause motor changes when administered alone. However the SS combined with amitriptyline increased the number of rearings (p=0,045) and reduced the immobility time (p=0.041).

Conclusions

SS exerted no motor effect, although flunarizine and propranolol could produced motor interference.

Downloads

Download data is not yet available.

References

- Bigal ME, Lipton RB, Stewart WF. The epidemiology and impact of migraine. CurrNeurolNeurosci Rep 2004;4(2):98-104. DOI: https://doi.org/10.1007/s11910-004-0022-8

- Silberstein SD. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology2000;55:754-62. DOI: https://doi.org/10.1212/WNL.55.6.754

- Comitê Ad Hoc da Sociedade Brasileira de Cefaléia. Recomendações para o tratamento profilático da migrânea: consenso da Sociedade Brasileira de Cefaléia. ArqNeuropsiquiatr2002;60(1):159-169. DOI: https://doi.org/10.1590/S0004-282X2002000100030

- Rizzo M. Impaired driving from medical conditions: A 70-year-old man trying to decide if he should continue driving. JAMA 2011;305:1018-1026. DOI: https://doi.org/10.1001/jama.2011.252

- Al-Quassab HK, Findley LJ. Comparison of propranolol LA 80 mg and propranolol LA 160 mg in migraine prophylaxis: a placebo controlled study. Cephalalgia 1993;13:128-131. DOI: https://doi.org/10.1046/j.1468-2982.1993.1302128.x

- Ye Q, Yan LY, Xue LJ, Wang Q, Zhou ZK, Xiao H, Wan Q. Flunarizine blocks voltage-gated Na(+) and Ca(2+) currents in cultured rat cortical neurons: A possible locus of action in the prevention of migraine.NeurosciLett. 2011;487(3):394-9 DOI: https://doi.org/10.1016/j.neulet.2010.10.064

- Jones BJ, Roberts DJ. The quantitative measurement of motor inco-ordination in naive mice using an accelerating rotarod. J PharmPharmacol. 1968 Apr;20(4):302-4. DOI: https://doi.org/10.1111/j.2042-7158.1968.tb09743.x

- Ali BH, Bashir AK, Tanira MO. Some effects of Cassia italica on the central nervous system in mice. J PharmPharmacol1979;49:500–4 DOI: https://doi.org/10.1111/j.2042-7158.1997.tb06831.x

- Crawley JN. Exploratory behavior models on anxiety in mice. NeurosciBiobehav Rev 1985;9:37-44. DOI: https://doi.org/10.1016/0149-7634(85)90030-2

- Boska MD, Welch KMA, Schultz L, Nelson J. Effects of the anti-migraine drug sumatriptan on muscle energy metabolism: relationship to side-effects. Cephalalgia 2000: 20, 39-44. DOI: https://doi.org/10.1046/j.1468-2982.2000.00009.x

- Amital D, Fostick L, Sasson Y, Kindler S, Amital H, Zohar J. Anxiogenic effects of Sumatriptan in panic disorder: a double-blind, placebo-controlled study. EurNeurophychopharmacol 2005;15:279-282. DOI: https://doi.org/10.1016/j.euroneuro.2004.12.002

- Gardner CR. Potencial use of drugs modulating 5HT activity in the treatment of anxiety. Gen Pharmacol 1988;19:347-356. DOI: https://doi.org/10.1016/0306-3623(88)90027-4

- Tatarczynska E, Klodzinska A, Stachowicz K, Chojnacka-Wojcik E. Effects of a selective 5 HT1B receptor agonist and antagonists in animal models of anxiety and depression. BehavPharmacol 2004;15:523-534. DOI: https://doi.org/10.1097/00008877-200412000-00001

- Morelli N, Gori S, Choub A, Maluccio MR, Orlandi G, Guazzelli M, Murri L. Do 5HT1B/1D receptor agonists have an effect on mood and anxiety disorders? Cephalalgia 2007;27:471-472. DOI: https://doi.org/10.1111/j.1468-2982.2007.01294.x

- Lin D, Parsons LH. Anxiogenic-like effect of serotonin 1B receptor stimulation in the rat elevated plus-maze. PharmacolBioch Behavior 2002;71:581-587. DOI: https://doi.org/10.1016/S0091-3057(01)00712-2

- Stern L, Zohar J, Cohen R, Sasson Y.Treatment of severe, drug resistant obsessive compulsive disorder with the 5HT1D agonist sumatriptan.EurNeuropsychopharmacol. 1998;8:325-328. DOI: https://doi.org/10.1016/S0924-977X(97)00092-8

- Koran LM, Pallanti S, Quercioli L. Sumatriptan, 5-HT1D receptors and obsessive–compulsive disorder. Eur. Neuropsychopharmacol. 2001;11: 169–172. DOI: https://doi.org/10.1016/S0924-977X(01)00082-7

- Stein DJ, Van Heerde B, Wessels CJ, Van Kradenburg J, Warwick J, Wasserman HJ. Single photon emission computed tomography of the brain with Tc-99 m HMPAO during sumatriptan challenge in obsessive–compulsive disorder: investigating the functional role of the serotonin auto-receptor. Prog.Neuropsychopharmacol. Biol. Psychiatry 1999;23:1079– 1099. DOI: https://doi.org/10.1016/S0278-5846(99)00051-2

Downloads

Published

2024-09-30

How to Cite

1.
Novak EM, Kowacs PA, Carvalho GA de, Savio MC, Augusto LP, Borges CR, Gustavo Ribas, Guinski GC, Sandra Monarin, Utiumi MAT, Piovesan Élcio J. The influence between migraine preven drugs and sumatriptan succinate on motor activity. Headache Med [Internet]. 2024 Sep. 30 [cited 2024 Nov. 21];15(3):145-50. Available from: https://headachemedicine.com.br/index.php/hm/article/view/1026

Issue

Vol. 15 No. 3 (2024)

Section

Original

License

Copyright (c) 2024 Edison Matos Novak, Pedro André Kowacs, Guilherme Armando de Carvalho, Mariane Christina Savio, Lucas Pires Augusto, Conrado Regis Borges, Gustavo Ribas, Giovana Costa Guinski, Sandra Monarin, Marco Antonio Takashi Utiumi, Élcio Juliato Piovesan (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Most read articles by the same author(s)

<< < 1 2 3 4 > >>